BillionToOne, Inc. - Class A common stock (BLLN) Covered Calls

BillionToOne is a molecular diagnostics company that develops high-precision genetic testing solutions. Using its proprietary Quantitative Counting Templates (QCT) platform, the company provides ultrasensitive, single-molecule DNA quantification. Its primary focus areas include prenatal screening—offering non-invasive fetal risk assessment—and oncology, where it provides liquid biopsy tests to guide and monitor cancer therapy selection and patient response.

You can sell covered calls on BillionToOne, Inc. - Class A common stock to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for BLLN (prices last updated Mon 4:16 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

Core Business and Products

BillionToOne, Inc. (BLLN) is at the forefront of the precision medicine revolution. The company’s core technology is its Molecular Counting Platform, which overcomes the "noise" inherent in traditional Next-Generation Sequencing (NGS). By counting individual DNA molecules, BillionToOne can detect minute genetic variations applied across two primary verticals: prenatal screening (UNITY Screen) and quantitative oncology (Northstar Select/Response).

In the oncology space, these liquid biopsy tools allow clinicians to select targeted therapies and monitor how a patient’s tumor is responding to treatment in real-time by measuring circulating tumor DNA (ctDNA) with unprecedented sensitivity. This vertical integration aims to convert the company’s massive R&D leads into high-margin transaction and financing revenue in the clinical diagnostic market.

Competitive Landscape

The molecular diagnostics market is highly competitive and rapidly evolving. BLLN competes with established diagnostic giants and specialized genomic testing firms. While the sector is sensitive to reimbursement policies and FDA regulatory shifts, BillionToOne’s 2026 guidance suggests an aggressive capture of market share due to its superior analytical sensitivity. Unlike many smaller biotech firms, BLLN maintains a liquid options chain, making it a favorite for investors managing risk in the volatile healthcare services sector.

Key competitors and peers in the molecular diagnostics and genomics space include:

1. Illumina, Inc. (ILMN): The global leader in DNA sequencing technology, providing the primary hardware infrastructure for the genomics industry.
2. Guardant Health, Inc. (GH): A primary competitor in the liquid biopsy and oncology monitoring space.
3. Natera, Inc. (NTRA): A direct rival in the NIPT and oncology markets, using a competitive personalized genetic testing approach.
4. Hims & Hers Health, Inc. (HIMS): While focused on consumer health, it represents a liquid, optionable peer in the "Health Care Services" sector frequently compared by analysts.

Strategic Outlook and Innovation

As of April 2026, BillionToOne is transitioning from a high-growth startup to a scaled diagnostic powerhouse. The company recently issued 2026 revenue guidance of $415M–$430M, driven by the expansion of its Northstar oncology suite. Management is focused on reaching sustained GAAP profitability by leveraging the efficiency of its molecular counting technology, which requires less sequencing depth—and thus lower cost—than traditional methods.

Want more examples? BLKB Covered Calls | BLMN Covered Calls